glp 1 prescription canada approves first generic GLP-1 drug in G7 WHO Conditionally Recommends GLP-1 Therapies

Results announced in December 2025 confirmed the Phase 2 findings at a longer timepoint (Lilly Press Release, Dec 2025): The 28.7% weight loss at 68 weeks exceeds both semaglutide (~15% in STEP trials) and tirzepatide (~22.5% in SURMOUNT trials) at similar timepoints

In the STEP-2 study 36 , semaglutide 2.4 mg showed a 6.0% incidence of psychiatric events compared to 3.7% in the placebo group

The Institute for Clinical and Economic Review (ICER) found that the lifetime employer cost for Wegovy would be $274,400 , while the medical costs averted over a lifetime would be $61,600

In other words, Zepbound helps you feel full for a longer amount of time, which prevents you from consuming more calories throughout the day

What is the future outlook for oral GLP-1 medications

Could reduced food intake place me at risk for a nutritional deficiency